Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer

Basch, 2014, Systemic therapy in men with metastatic castration-resistant prostate cancer. American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline, J Clin Oncol, 32, 3436, 10.1200/JCO.2013.54.8404 Grasso, 2012, The mutational landscape of lethal castration-resistant prostate cancer, Nature, 487, 239, 10.1038/nature11125 Beltran, 2013, Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity, Eur Urol, 63, 920, 10.1016/j.eururo.2012.08.053 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Beltran, 2014, Aggressive variants of castration-resistant prostate cancer, Clin Cancer Res, 20, 2846, 10.1158/1078-0432.CCR-13-3309 Tan, 2008, “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations, J Clin Oncol, 26, 5530, 10.1200/JCO.2008.16.1703 Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022 Scott, 2015, Poly (ADP-ribose) polymerase inhibitors: recent advances and future development, J Clin Oncol, 33, 1397, 10.1200/JCO.2014.58.8848 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 Pritchard, 2014, Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens, J Mol Diagn, 16, 56, 10.1016/j.jmoldx.2013.08.004